Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Gross Margin
Madrigal Pharmaceuticals Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
7.5B USD |
97%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.6B USD |
70%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
170.3B USD |
62%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
139.9B USD |
78%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
132B USD |
86%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
120.3B AUD |
52%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.4B USD |
87%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
33.5B EUR |
90%
|
Madrigal Pharmaceuticals Inc
Glance View
In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Madrigal Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 96.5%.
You don't have any saved screeners yet